Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

Journal of Experimental Medicine

Volumn 197, Issue 6, 2003, Pages 725-733

  Aktas, Orhan ^a   Waiczies, Sonia ^a   Smorodchenko, Alina ^a   Dörr, Jan ^a   Seeger, Bibiane ^a   Prozorovski, Timour ^a   Sallach, Stephanie ^a   Endres, Matthias ^a   Brocke, Stefan ^b   Nitsch, Robert ^a   Zipp, Frauke ^a,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HEBREW UNIVERSITY   (Israel)

^c Neuroscience Research Center   (Germany)

Author keywords

Autoimmunity; EAE; HMG CoA reductase; Multiple sclerosis; T cell

Indexed keywords

ATORVASTATIN; CYTOKINE; ENCEPHALITOGENIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; PROTEIN PLP 139-151; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CALCIUM TRANSPORT; CELL ADHESION; CELL CYCLE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC DISEASE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENCEPHALOMYELITIS; FEMALE; INCIDENCE; INFLAMMATION; MOUSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN TARGETING; RELAPSE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELL DIVISION; CELL LINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENES, MHC CLASS II; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; MICE; MICE, INBRED STRAINS; MYELIN PROTEOLIPID PROTEIN; PARALYSIS; PEPTIDE FRAGMENTS; PYRROLES; RECURRENCE; SPINAL CORD; TH1 CELLS;

EID: 0037451121     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20021425     Document Type: Article

References (42)

1. Maron, D.J., S. Fazio, and M.F. Linton. 2000. Current perspectives on statins. Circulations. 101:207-213.
2. Albert, M.A., E. Danielson, N. Rifai, and P.M. Ridker. 2001. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286:64-70.
3. Ridker, P.M., N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles, and A.M. Gotto. 2001. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344:1959-1965.
4. Kobashigawa, J.A., S. Katznelson, H. Laks, J.A. Johnson, L. Yeatman, X.M. Wang, D. Chia, P.I. Terasaki, A. Sabad, G.A. Cogert, et al. 1995. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:621-627.
5. Kwak, B., F. Mulhaupt, S. Myit, and F. Mach. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:1399-1402.
6. Weitz-Schmidt, G., K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:687-692.
7. Palinski, W. 2000. Immunomodulation: a new role for statins? Nat. Med. 6:1311-1312.
8. Miller, S.D., and W.J. Karpus. 1994. The immunopathogenesis and regulation of T cell-mediated demyelinating diseases. Immunol. Today. 15:356-361.
9. Raine, C.S., and U. Traugott. 1984. Experimental autoimmune demyelination. Chronic relapsing models and their therapeutic implications for multiple sclerosis. Ann. NY Acad. Sci. 436:33-51.
10. Zamvil, S.S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:579-621.
11. Goverman, J., and T. Brabb. 1996. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Lab. Anim. Sci. 46:482-492.
12. Constantin, G., S. Brocke, A. Izikson, C. Laudanna, and E. Butcher. 1998. Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoinmmne encephalomyelitis. Eur. J. Immunol. 28:3523-3529.
13. Brocke, S., A. Gaur, C. Piercy, A. Gautam, K. Gijbels, C.G. Fathman, and L. Steinman. 1993. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature. 365:642-644.
14. Jansson, M., V. Panoutsakopoulu, J. Baker, L. Klein, and H. Cantor. 2002. Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 168:2096-2099.
15. Wendling, U., H. Walczak, J. Dörr, C. Jacobi, M. Weller, P.H. Krammer, and F. Zipp. 2000. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. Cell Death Differ. 7:637-644.
16. Lünemann, J.D., S. Waiczies, S. Ehrlich, U. Wendling, B. Seeger, T. Kamradt, and F. Zipp. 2002. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J. Immunol. 168:4881-4888.
17. Brocke, S., L. Quigley, H.F. McFarland, and L. Steinman. 1996. Isolation and characterization of autoreactive T cells in experimental autoimmune encephalomyelitis of the mouse. Methods Enzymol. 9:458-462.
18. Griffioen, A.W., G.T. Rijkers, J. Keij, and B.J. Zegers. 1989. Measurement of cytoplasmic calcium in lymphocytes using flow cytometry. Kinetic studies and single cell analysis. J. Immunol. Methods. 120:23-27.
19. Smith, T., A. Groom, B. Zhu, and L. Turski. 2000. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6:62-66.
20. Vanderlugt, C.L., S.M. Rahbe, P.J. Elliott, M.C. Dal Canto, and S.D. Miller. 2000. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J. Autoimmun. 14:205-211.
21. Bisgaier, C.L., A.D. Essenburg, B.J. Auerbach, M.E. Pape, C.S. Sekerke, A. Gee, S. Wolle, and K.S. Newton. 1997. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J. Lipid Res. 38:2502-2515.
22. Johnston, T.P., L.B. Nguyen, W.A. Chu, and S. Shefer. 2001. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int. J. Pharm. 229:75-86.
23. van de Poll, S.W., T.J. Romer, O.L. Volger, D.J. Delsing, T.C. Bakker Schut, H.M. Princen, L.M. Havekes, J.W. Jukema, A. van der Laarse, and G.J. Puppels. 2001. Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice. Arterioscler. Thromb. Vasc. Biol. 21:1630-1635.
24. Endres, M., U. Laufs, Z. Huang, T. Nakamura, P. Huang, M.A. Moskowitz, and J.K. Liao. 1998. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 95:8880-8885.
25. Laufs, U., K. Gertz, P. Huang, G. Nickenig, M. Bohm, U. Dirnagl, and M. Endres. 2000. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 31:2442-2449.
26. Boberg, M., R. Angerbauer, W.K. Kanhai, W. Karl, A. Kern, M. Radtke, and W. Steinke. 1997. Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metab. Dispos. 26:640-652.
27. Bernini, F., A. Poli, and R. Paoletti. 2001. Safety of HMG- CoA reductase inhibitors: focus on atorvastatin. Cardiovasc. Drugs Ther. 15:211-218.
28. Black, A.E., M.W. Sinz, R.N. Hayes, and T.F. Woolf. 1998. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydro-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 26:755-763.
29. Stern, R.H., B.B. Yang, N.J. Hounslow, M. MacMahon, R.B. Abel, and S.C. Olson. 2000. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 40:616-623.
30. Panitch, H., R.L. Hirsch, J. Schindler, and K.P. Johnson. 1987. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 37:1097-1102.
31. Tran, E.H., E.N. Prince, and T. Owens. 2000. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164:2759-2768.
32. Tanuma, N., T. Shin, K. Kogure, and Y. Matsumoto. 1999. Differential role of TNF-alpha and IFN-gamma in the brain of rats with chronic relapsing autoimmune encephalomyelitis. J. Neuroimmunol. 96:73-79.
33. Lea, A.P., and D. McTavish. 1997. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 53:828-847.
34. Chirathaworn, C., J.E. Kohlmeier, S.A. Tibbetts, L.M. Rumsey, M.A. Chan, and S.H. Benedict. 2002. Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J. Immunol. 168:5530-5537.
35. Stanislaus, R., A.K. Singh, and I. Singh. 2001. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 66:155-162.
36. Liao, J.K. 2002. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110:285-288.
37. Blanco-Colio, L.M., A. Villa, M. Ortego, M.A. Hernandez-Presa, A. Pascual, J.J. Plaza, and J. Egido. 2002. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 161:17-26.
38. Youssef, S., O. Stüve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, E.M. Hur, M. Bravo, D.J. Mitchell, R.A. Sobel, L. Steinman, and S.S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:78-84.
39. Naderi, S., R. Blomhoff, J. Myklebust, E.B. Smeland, B. Erikstein, K.R. Norum, and H.K. Blomhoff. 1999. Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Exp. Cell Res. 252:144-153.
40. Danesh, F.R., M.M. Sadeghi, N. Amro, C. Philips, L. Zeng, S. Lin, A. Sahai, and Y.S. Kanwar. 2002. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc. Natl. Acad. Sci. USA. 99:8301-8305.
41. Hughes, D.A. 1995. Control of signal transduction and morphogenesis by Ras. Semin. Cell Biol. 6:89-94.
42. Hengst, L., and S.I. Reed. 1996. Translational control of p27Kip1 accumulation during the cell cycle. Science. 271:1861-1864.